Welcome to LookChem.com Sign In|Join Free

CAS

  • or

4160-61-6

Post Buying Request

4160-61-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

4160-61-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 4160-61-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,1,6 and 0 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 4160-61:
(6*4)+(5*1)+(4*6)+(3*0)+(2*6)+(1*1)=66
66 % 10 = 6
So 4160-61-6 is a valid CAS Registry Number.

4160-61-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name Methyl tetrahydro-4-oxo-2H-thiopyran-3-carboxylate

1.2 Other means of identification

Product number -
Other names Methyl 4-oxotetrahydro-2H-thiopyran-3-carboxylate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:4160-61-6 SDS

4160-61-6Relevant articles and documents

New Reaction Mode of the Dieckmann-Type Cyclization under the Lewis Acid-Et3N Conditions

Tamai, Satoshi,Ushirogochi, Hideki,Sano, Shigeki,Nagao, Yoshimitsu

, p. 295 - 296 (1995)

Dieckmann-type cyclization reactions of various dicarboxylic acid derivatives were readily promoted by employing Lewis acids such as AlCl3, MgBr2, MgCl2, and Sn(OSO2CF3)2 in the presence of Et3N or N-ethylpiperidine.The cyclization reactions of half thiol

Discovery of Novel Dihydrothiopyrano[4,3-d]pyrimidine Derivatives as Potent HIV-1 NNRTIs with Significantly Reduced hERG Inhibitory Activity and Improved Resistance Profiles

Wang, Zhao,Zalloum, Waleed A.,Wang, Wenbo,Jiang, Xiangyi,De Clercq, Erik,Pannecouque, Christophe,Kang, Dongwei,Zhan, Peng,Liu, Xinyong

, p. 13658 - 13675 (2021/09/13)

Enlightened by the available structural biology information, a novel series of dihydrothiopyrano[4,3-d]pyrimidine derivatives were rationally designedviascaffold hopping and molecular hybridization strategies. Notably, compound 20a yielded exceptionally potent antiviral activities (EC50= 4.44-54.5 nM) against various HIV-1 strains and improved resistance profiles (RF = 0.5-5.6) compared to etravirine and rilpivirine. Meanwhile, 20a exhibited reduced cytotoxicity (CC50= 284 μM) and higher SI values (SI = 5210-63992). Molecular dynamics simulations were performed to rationalize the distinct resistance profiles. Besides, 20a displayed better solubility (sol. = 12.8 μg/mL) and no significant inhibition of the main CYP enzymes. Furthermore, 20a was characterized for prominent metabolic stability andin vivosafety properties. Most importantly, the hERG inhibition profile of 20a (IC50= 19.84 μM) was a remarkable improvement. Overall, 20a possesses huge potential to serve as a promising drug candidate due to its excellent potency, low toxicity, and favorable drug-like properties.

Preparation and application of 2-aminopyrimidine heterocyclic compounds containing 4-acylamino phenoxy

-

Paragraph 0076-0078, (2020/10/14)

The invention relates to preparation and application of 2-aminopyrimidine heterocyclic compounds containing 4-acylamino phenoxy as shown in general formulas I and II, and pharmaceutically acceptable salts, hydrates, solvates and prodrugs of the compounds. Substituents X, R1 and R2 have meanings given in the specification. The compounds shown in the general formulas I and II have a strong effect ofinhibiting EGFR, EGFRT790M/L858R and EGFRT790M kinase; the compounds have very low inhibitory activity on human normal hepatocyte LO2. The invention also relates to application of the compounds and pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof in preparation of drugs for treating diseases caused by abnormal activation and high expression of EGFR kinase and positive mutation of T790M and L858R, particularly application in preparing medicines for treating and/or preventing cancers.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 4160-61-6